$1.53
1.29%
Nasdaq, Jan 02, 10:02 pm CET
ISIN
US29446K1060
Symbol
EQ

Equillium, Inc. Stock price

$1.53
+0.67 78.05% 1M
+1.21 380.38% 6M
-0.02 1.29% YTD
+0.76 99.01% 1Y
+0.47 44.34% 3Y
-3.50 69.58% 5Y
-12.47 89.07% 10Y
-12.47 89.07% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.02 1.29%
ISIN
US29446K1060
Symbol
EQ
Industry

Key metrics

Basic
Market capitalization
$93.2m
Enterprise Value
$60.1m
Net debt
positive
Cash
$33.1m
Shares outstanding
60.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
21.2 | -
EV/Sales
13.7 | -
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
74.5%
Return on Equity
-42.3%
ROCE
-77.6%
ROIC
-8,529.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.4m | $0.0
EBITDA
$-24.2m | -
EBIT
$-24.4m | $-25.0m
Net Income
$-24.4m | $-46.3m
Free Cash Flow
$-22.7m
Growth (TTM | estimate)
Revenue
-90.4% | -100.0%
EBITDA
-265.1% | -
EBIT
-259.9% | -202.7%
Net Income
-428.6% | -473.1%
Free Cash Flow
-4.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-551.9% | -
EBIT
-554.9%
Net
-555.9% | -
Free Cash Flow
-515.7%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
2.0%
Employees
35
Rev per Employee
$1.2m
Show more

Is Equillium, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Equillium, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Equillium, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Equillium, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Equillium, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4.39 4.39
90% 90%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
24% 24%
231%
- Research and Development Expense 19 19
53% 53%
424%
-24 -24
265% 265%
-552%
- Depreciation and Amortization 0.13 0.13
7% 7%
3%
EBIT (Operating Income) EBIT -24 -24
260% 260%
-555%
Net Profit -24 -24
429% 429%
-556%

In millions USD.

Don't miss a Thing! We will send you all news about Equillium, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Equillium, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
about 2 months ago
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned f...
Neutral
Seeking Alpha
about 2 months ago
Equillium, Inc. ( EQ ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases November 5, 2025 12:00 PM EST Company Participants Bruce Steel - Co-Founder, CEO & Director Stephen Connelly - Chief Scientific Officer & President Francisco Quintana Brian Gordon Feagan Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Cha ...
More Equillium, Inc. News

Company Profile

Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO Bruce Steel
Employees 35
Founded 2017
Website www.equilliumbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today